30-05-2025
AstraZeneca gets CDSCO nod for lung cancer drug
New Delhi: AstraZeneca India Pharma on Thursday said it has received approval from the Central Drugs Standard Control Organisation (CDSCO) for Osimertinib tablets in strength of 40mg and 80mg. The approval marks a critical step forward with Osimertinib as monotherapy in the treatment of patients with locally advanced, unresectable (Stage III) non-small cell lung cancer, it added.
